

ADTnorm: Robust Integration of Single-cell Protein Measurement across CITE-seq Datasets

Raphael Gottardo

Raphael.Gottardo@chuv.ch

Biomedical Data Science Center and Swiss Institute of Bioinformatics, Faculty of Biology and Medicine,
University of Lausanne <https://orcid.org/0000-0002-3867-0232>

Ye Zheng

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center

Daniel Caron

Columbia University Irving Medical Center <https://orcid.org/0000-0002-1500-8713>

Ju Kim

Fred Hutchinson Cancer Center

Seong Jun

University of Rochester Medical Center

Yuan Tian

Fred Hutchinson Cancer Center

Florian Mair

Institute of Molecular Health Sciences <https://orcid.org/0000-0001-6732-5449>

Kenneth Stuart

Seattle Children's Research Institute

Peter Sims

Columbia University Irving Medical Center <https://orcid.org/0000-0002-3921-4837>

Brief Communication

Keywords:

Posted Date: July 8th, 2024

DOI: <https://doi.org/10.21203/rs.3.rs-4572811/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: Yes there is potential Competing Interest. Raphael Gottardo has received consulting income from Takeda and Sanofi and discloses ownership in Ozette Technologies. Additionally, Raphael Gottardo declares research collaborations with Owkin and 10X Genomics. Other authors declare no competing financial interests.

ADTnorm: Robust Integration of Single-cell Protein Measurement across CITE-seq Datasets

Ye Zheng^{1,2+}, Daniel P. Caron³⁺, Ju Yeong Kim², Seong-Hwan Jun⁴, Yuan Tian², Mair Florian⁵, Kenneth D. Stuart⁶, Peter A. Sims^{7,8}, Raphael Gottardo^{2,9*}

¹ Basic Science Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA

² Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA

³ Department of Microbiology and Immunology, Columbia University, New York, NY 10032, USA

⁴ Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY 14642, USA

⁵ Department of Biology, ETH Zürich, Zürich 8093, Switzerland

⁶ Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States

⁷ Department of Systems Biology, Columbia University, New York, NY 10032, USA

⁸ Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA

⁹ Biomedical Data Science Center, Lausanne University Hospital and University of Lausanne, Lausanne 1005, Switzerland

+ These authors contributed equally to this work.

* Corresponding author. Email: raphael.gottardo@chuv.ch

Abstract

CITE-seq enables paired measurement of surface protein and mRNA expression in single cells using antibodies conjugated to oligonucleotide tags. Due to the high copy number of surface protein molecules, sequencing antibody-derived tags (ADTs) allows for robust protein detection, improving cell-type identification. However, variability in antibody staining leads to batch effects in the ADT expression, obscuring biological variation, reducing interpretability, and obstructing cross-study analyses. Here, we present ADTnorm (<https://github.com/yezhengSTAT/ADTnorm>), a normalization and integration method designed explicitly for ADT abundance. Benchmarking against 14 existing scaling and normalization methods, we show that ADTnorm accurately aligns populations with negative- and positive-expression of surface protein markers across 13 public datasets, effectively removing technical variation across batches and improving cell-type separation. ADTnorm enables efficient integration of public CITE-seq datasets, each with unique experimental designs, paving the way for atlas-level analyses. Beyond normalization, ADTnorm includes built-in utilities to aid in automated threshold-gating as well as assessment of antibody staining quality for titration optimization and antibody panel selection. Applying ADTnorm to a published COVID-19 CITE-seq dataset allowed for identifying previously undetected disease-associated markers, illustrating a broad utility in biological applications.

24 Main

25 Recent advances in single-cell multimodal profiling, such as Cellular Indexing of Transcrip-
26 tomes and Epitopes by sequencing (CITE-seq), have enabled the paired profiling of gene ex-
27 pression alongside surface protein expression¹⁻⁴. This paired multimodal profiling of single
28 cells has allowed researchers to achieve more precise cell-type annotation (e.g., of immune
29 cells)^{5,6}, study the relationship between transcriptomic state and surface phenotype⁷⁻⁹, and
30 readily adapt results to flow cytometry for validation^{1,4}. Given its extraordinary potential, there
31 is increasing application of CITE-seq for atlas construction¹⁰⁻¹² and in large cohort disease-
32 related studies¹³⁻¹⁵. To effectively leverage the data being generated, there is a pressing need
33 for computational tools for CITE-seq data integration across studies.

34 Surface proteome profiling by CITE-seq gives rise to specific data characteristics and
35 sources of technical noise inherent to antibody staining. Owing to the high copy number of
36 surface proteins and efficient molecular capture of antibody-derived tags (ADTs), protein ex-
37 pression is considerably less sparse than other single-cell modalities such as mRNA expression
38 or genome-wide chromatin accessibility. Consequently, the protein expression captured by
39 CITE-seq often closely matches the information-rich multi-peak density distributions observed
40 in flow cytometry¹ (Supplementary Fig. 1A). Density distributions of protein expression of
41 CITE-seq data frequently exhibit a negative peak, representing background signal arising from
42 non-specifically bound or unbound (free-floating) antibody¹⁶, and one or more positive peak(s)
43 representing cells expressing the target protein. Similar to fluorescence-based techniques, the
44 signal-to-noise ratio between the negative- and positive-expression peak(s) is highly sensitive to
45 antibody staining conditions, including antibody concentrations¹⁷, staining volumes and time¹⁸,
46 and antibody panel composition¹⁹. Because of these unique considerations, the normalization
47 and integration approaches devised for other single-cell modalities may not be directly trans-
48 latable, highlighting the need for methodologies tailored to the intricacies of protein data.

49 Recent normalization algorithms designed for CITE-seq data, similar to established
50 scRNA-seq approaches^{20,21}, have primarily focused on modeling sequencing bias and ambi-
51 ent expression to remove background signals. Centered log-ratio (CLR) normalization was
52 initially proposed for CITE-seq¹, using library size to account for variable sequencing depth
53 and cell size. However, unlike scRNA-seq, which offers relatively unbiased transcriptional
54 profiling, CITE-seq protein panels target only a handful of manually selected proteins, typi-
55 cally between 10 and 300. Therefore, the overall ADT library size is highly sensitive to panel
56 composition, can be easily skewed by high expression of a few subset-specific proteins, and
57 unreliably reflects sequencing depth or cell size. More sophisticated algorithms, including
58 totalVI²², DSB¹⁶, and DecontPro²³, attempt to model ambient contamination and remove or
59 re-center the background-signal to zero. However, these negative-expression peaks in ADT
60 abundance mirror expression distributions by conventional cytometry and are essential for re-
61 liable threshold-gating of cells for cell-type annotation²⁴. Improper or incomplete removal of
62 background ADT expression can make it difficult to distinguish between negative-, mid-, and
63 high-expression peaks, for example, in the trimodal expression of the surface marker CD4, a

64 T cell lineage marker. Consequently, normalization of the negative peak in CITE-seq should
65 emphasize its essential role in cell-type identification rather than its artificial removal.

66 Instead of individually modeling each source of noise, we constructed a non-parametric
67 strategy, ADTnorm, building on methods originally conceived for cytometry data²⁵ to re-
68 move the batch effects through strategic peak identification and alignment. ADTnorm uses
69 a curve registration algorithm²⁶ to identify protein density landmarks, including the nega-
70 tive and positive peaks, and relies on local minima to detect the valleys separating adja-
71 cent peaks. Employing a functional data analysis approach²⁷, ADTnorm normalizes pro-
72 tein expression by aligning the landmarks across datasets (Fig. 1A and Methods), effectively
73 simulating a scenario where all data are derived from the same experiment with equiva-
74 lent background and antibody staining quality. ADTnorm is implemented as an R package
75 (<https://github.com/yezhenSTAT/ADTnorm>) with an interactive graphical user
76 interface to simplify landmark adjustments (Supplementary Fig. 1B) and a Python wrapper
77 (<https://github.com/donnafarberlab/ADTnormPy>) available to facilitate ADT-
78 norm’s integration into existing CITE-seq analysis workflows (Supplementary Note).

79 Leveraging 13 public CITE-seq datasets (Supplementary Table 1), we benchmarked the
80 integration performance of ADTnorm against 14 methods from three broad groups: (1) scaling
81 methods commonly applied to cytometry and single-cell data, including Arcsinh transforma-
82 tion, CLR¹, log-transformation of count per million (logCPM), and a hybrid approach com-
83 bining Arcsinh and CLR transformations (Arcsinh + CLR); (2) popular single-cell batch ef-
84 fect removal tools, including Harmony²⁸ implemented on the raw counts, arcsinh-transformed,
85 CLR-transformed or logCPM-transformed data, fastMNN²⁹, and CytofRUV³⁰; and (3) methods
86 tailored to CITE-seq normalization, including DSB¹⁶, decontPro²³, totalVI²², and sciPENN⁸.
87 Across 13 datasets, ADTnorm effectively reduced batch variability, such that negative and
88 positive populations for each surface protein marker could be consistently identified across
89 studies (Fig. 1B, protein density distributions in Supplementary Note). UMAP embeddings
90 of the normalized ADT expression revealed effective batch integration by ADTnorm while
91 preserving cell type separation at both broad and refined annotation levels, treating either the
92 study-level or individual samples as batches (Supplementary Figs. 2-3). ADTnorm applied us-
93 ing default landmark detection (default) or manually adjusted landmark detection (customized;
94 Methods) outperformed other tools in balancing cell-type separation with cross-study batch
95 effect removal as quantified by Silhouette scores, Adjust Rand Index (ARI), and the Local In-
96 verse Simpson’s Index (LISI) (Methods; Fig. 1C and Supplementary Fig. 4A-C). Furthermore,
97 ADTnorm can facilitate the seamless integration of new datasets without reprocessing existing
98 ones by aligning landmarks to predetermined locations (Supplementary Note). It can also in-
99 corporate users’ prior knowledge about a batch’s cell type composition. For example, because
100 the *Buus 2021 T* cell dataset is composed of only T cells, ADTnorm is adjusted to align the
101 singular peak in CD3 as positive-expression (Fig. 1B and Supplementary Note). ADTnorm
102 is also highly scalable, with a fast processing speed and low memory consumption compared
103 to other methods (Supplementary Fig. 4D-E). Also, ADTnorm is designed to process protein

104 markers independently, allowing adaption to parallel processing.

105 We next explored the downstream impact of protein normalization on joint embeddings
106 of RNA and protein data. Following batch-correction of ADT expression by the above meth-
107 ods and batch-correction of the RNA expression using reciprocal PCA¹⁰, we computed the
108 multimodal embedding using the weighted nearest neighbor (WNN) algorithm¹⁰ (Supplemen-
109 tary Fig. 5A and Methods). As totalVI and sciPENN already incorporate gene expression
110 into their protein normalization process, we omitted them from the WNN integration compari-
111 son. As expected, methods with sub-optimal removal of ADT batch effects resulted in skewed
112 WNN integration (Supplementary Fig. 6). ADTnorm markedly minimized batch influences
113 and achieved superior accuracy in segregating cell types as quantified by ARI (Supplementary
114 Fig. 5B), underscoring its utility in post-normalization multimodal integration.

115 As surface protein expression varies across cell types, batch correction may be sensitive
116 to variable subset composition across batches. To evaluate the resilience of normalization meth-
117 ods, we subsampled specific cell subsets from a few batches, devising three scenarios featuring
118 increasingly skewed cell-type compositions (Methods). Careful examination revealed that Har-
119 mony, fastMNN, and CytofRUV were highly sensitive to compositional differences, produc-
120 ing unexpected and inaccurate results. For example, CD19 is a highly specific B cell-lineage
121 marker. However, in some batches, Harmony- and fastMNN-normalized CD19 expression was
122 significantly higher in CD4 T cells than in CD8 T cells, and CytofRUV-normalized CD19 ex-
123 pression in CD8 T cells was comparable to that in B cells, patterns not supported by biological
124 expectations (Fig. 1D and Supplementary Fig. 7). Similar discrepancies were noted with DSB,
125 totalVI, and sciPENN across other vital lineage markers (Supplementary Figs. 8-9). ADTnorm
126 distinguishes itself by meticulously preserving the ranking of protein expression across cells
127 within each batch, thereby reducing the risk of biologically irrelevant anomalies.

128 Beyond its primary role in batch correction, ADTnorm leverages intermediate landmark
129 detection results to perform automated threshold-gating (auto-gating) for cell type annotation
130 and to assess staining quality to aid in the optimization of CITE-seq experiments (Methods).
131 Valley landmarks identified during ADTnorm normalization can be used to perform automated
132 cell type annotation using predefined gating rules (Supplementary Table 2; Supplementary
133 Fig. 10A-C). While ADTnorm auto-gating showcased high accuracy for a majority of the stud-
134 ies, achieving between 80-100% for comprehensive and nuanced cell type distinctions, auto-
135 gating was underperformed for dendritic cells, memory CD4 T and memory CD8 T cells in
136 the *Hao 2020*, *Kotliarov 2020*, and *Witkowski 2020* datasets (Fig. 1E). Auto-gating accuracy is
137 likely influenced by the marker staining quality. Hence, we introduced a stain quality score,
138 inspired by fluorescent stain index³¹, to detect protein markers with poor signal-to-noise separa-
139 tion (Methods; Supplementary Fig. 1C). Low-quality scores are suggestive of under-optimized
140 staining conditions, which need careful evaluation or potential exclusion from downstream
141 analyses. Leveraging ADTnorm to assess staining quality revealed that CD56 and CD45RA,
142 which are markers used for gating dendritic and memory T cells, featured less distinct peak sep-
143 aration in batches with poor auto-gating performance (Fig. 1F and Supplementary Fig. 10D).

144 To effectively stain for surface protein, antibody concentrations must be carefully tuned
145 for each sample type. Sufficient antibodies are essential for positive-expression signal(s) to
146 overcome background, but an overabundance of antibodies can obscure rare or low-expression
147 markers by increasing background noise and can increase experimental costs. Although down-
148 stream analysis can often tolerate suboptimal staining conditions, variable staining quality is a
149 major source of batch artifacts across samples and laboratories. To explore whether our stain
150 quality score is sensitive enough for titration optimization and to evaluate ADTnorm's ability to
151 mitigate these batch effects, we utilized a titration CITE-seq study that analyzed 124 antibodies
152 on human peripheral blood mononuclear cells (PBMCs)¹⁷. This study categorized antibody
153 titration into four levels, including the manufacturer's recommended concentration (1x) and
154 adjustments to 1/25x, 1/5x, and double (2x) the recommended concentration. As anticipated,
155 the higher concentrations (1x and 2x) typically yielded more distinct separation between nega-
156 tive and positive cell populations, whereas lower concentrations led to greater overlap between
157 negative and positive populations or failed to identify any positive population (Fig. 2A and Sup-
158 plementary Note). These trends were reflected in the stain quality scores, where markers with
159 reduced separation at low antibody concentrations exhibited lower scores (Fig. 2B). Notably,
160 conventional normalization methods were unable to successfully integrate expression across
161 titration batches (Supplementary Fig. 11 and Supplementary Note), but ADTnorm could ef-
162 fectively align negative and positive populations across concentrations, thus rescuing cell type
163 discrimination for many protein markers profiled using sub-optimal staining conditions (Sup-
164 plementary Fig. 12) and minimizing batch effects (Fig. 2A). For markers at low titrations that
165 exhibited no positive population, ADTnorm could only align the negative populations (Supple-
166 mentary Fig. 13A). In these cases, excessively low stain quality scores could alert researchers
167 of protein markers that consistently show poor discrimination, suggesting a potential need for
168 revising antibody titration or selection (Fig. 2B and Supplementary Fig. 13B). We also as-
169 sessed the influence of antibody titration on ADTnorm's auto-gating accuracy, finding that
170 auto-gating accuracy remains stable as long as lineage markers had detectable positive staining
171 (Supplementary Fig. 14).

172 We next explored whether ADTnorm could facilitate the analysis of consortium efforts.
173 Three UK medical centers profiled 192 protein markers using CITE-seq to study COVID-19
174 immune response across a diverse cohort of over 100 healthy donors and COVID-19 patients¹³.
175 Staining quality was highly variable across the participating medical centers (Fig. 2C). Specif-
176 ically, samples from Newcastle (Ncl) exhibited reduced separation between negative and pos-
177 itive peaks, whereas samples from Cambridge and Sanger displayed robust separation and a
178 higher frequency of detectable positive signals (Supplementary Figs. 15-16). These batch ef-
179 fects could not be effectively mitigated by other tools (Fig. 2C, Supplementary Fig. 17 and
180 Supplementary Note). ADTnorm effectively reduced technical artifacts (Fig. 2C), resulting in
181 improved cell type separation, both at the broad and refined annotation levels and also in the
182 joint RNA and ADT embedding (Supplementary Fig. 18).

183 Leveraging ADTnorm's integration and auto-gating, we next aimed to identify whether

184 the expression of specific surface markers could be associated with COVID-19 disease (Sup-
185 plementary Fig. 16E). Previous studies have identified compositional changes in the immune
186 compartment associated with disease, including increases in the frequency of specific monocyte
187 subsets in the PBMC compartment of mild, moderate, and severe COVID-19 patients (as noted
188 in Fig. 1c of the original publication¹³). Other studies have identified biomarkers on blood
189 monocytes associated with COVID-19 and type-I interferon signaling, including CD38^{32,33},
190 CD64^{34,35} and CD169^{36,37}. We sought to identify whether these trends could be attributed to
191 changing subset frequencies within the monocyte compartment or to the upregulation of these
192 markers across multiple subsets of monocytes. We analyzed the percent-positivity of these and
193 other markers on CD14⁺, CD16⁺, and CD83⁺CD14⁺ monocytes, and observed upregulation
194 of these markers among COVID-19 patients compared to healthy donors across multiple mono-
195 cytes states (Fig. 2D-E and Supplementary Fig. 19A). Such upregulation mirrors the trends
196 observed in scRNA-seq (Supplementary Fig. 19B). The normalization employed in the orig-
197 inal publication, DSB, did not accurately represent these trends, masking positive expression
198 of CD169 (Supplementary Fig. 20), failing to identify upregulation of CD169 with COVID-19
199 in any monocyte subset, and reducing signal of CD38 and CD64 in CD16 monocytes (Supple-
200 mentary Fig. 19C). This demonstrates the utility of ADTnorm in isolating biologically relevant
201 changes and uncovering previously concealed insights in surface protein expression.

202 In summary, ADTnorm offers a fast, precise, and scalable solution for normalizing pro-
203 tein expression data, effectively minimizing batch artifacts within studies and enabling inte-
204 gration across studies. ADTnorm is designed for high adaptability, allowing for normalization
205 at various batch levels, supporting missing data, and incorporating prior cell type knowledge.
206 By addressing protein batch effects, ADTnorm also improves multimodal aggregation of RNA
207 and protein modalities, enhancing cell type discrimination and improving interpretability. Un-
208 like other normalization methods that may introduce abnormal expression artifacts, ADTnorm
209 maintains the ranked order of cells within batches for expression of each protein marker and
210 delivers consistent performance across datasets with uneven cell type compositions. Addition-
211 ally, its auto-gating feature offers an expedited avenue for cell-type annotation. The integrated
212 stain quality scoring system alerts researchers to suboptimal staining and assesses experiment
213 quality, aiding in the calibration of antibody titration for pilot studies tailored to specific tis-
214 sue systems. Among positive-expressing populations, ADTnorm's landmark registration ap-
215 proach homogenizes variations in enrichment strength across samples. While it is possible
216 that these variations represent biological differences, that interpretation is confounded by many
217 sources of technical noise, including antibody concentrations, staining conditions, and sequenc-
218 ing artifacts. Notably, ADTnorm also preserves information about the proportion of positive-
219 expressing events in each batch, offering valuable insights into disease status, as exemplified
220 in the COVID-19 case study. This feature underscores the potential of ADTnorm to transcend
221 mere normalization, contributing to the identification of disease-associated protein markers.


222 Due to ADTnorm's high adaptability, we expect its utility may also extend beyond CITE-
223 seq, allowing for the harmonization of protein expression across multiple technologies (e.g.,

224 flow cytometry, CyTOF, and CITE-seq together). Its application is also primed for expansion
225 to multimodal assays by leveraging the normalized protein data as a bridge for cross-modality
226 integration, such as scCUT&Tag-pro³⁸, ASAP-seq³⁹ and PHAGE-ATAC⁴⁰, which profile sur-
227 face proteins alongside epigenomic or chromatin accessibility features. ADTnorm stands as a
228 pivotal tool in the evolving landscape of genomic research, facilitating comprehensive analyses
229 across a broad spectrum of biological conditions and technological platforms.

230 **Acknowledgments** This work was supported by the National Institutes of Health grant,
231 HG012797, to Y.Z. and Chan Zuckerberg Initiative award, DI-0000000345, to R.G.. D.P.C.
232 was supported by the Columbia University Graduate Training Program in Microbiology and
233 Immunology (T32AI106711). P.A.S. was supported by U19AI128949. We also acknowledge
234 the Scientific Computing Infrastructure at Fred Hutchinson Cancer Center funded by ORIP
235 grant S10OD028685, the J. Orin Edson Foundation, the Translational Data Science Integrated
236 Research Center of the Fred Hutchinson Cancer Center, and NIH U19AI128914. We also ap-
237 preciate the timely and in-depth discussion with Drs. Helen Lindsay, Bernat Bramon Mora and
238 Antonin Thiebaut from the University of Lausanne.


239 **Author Contributions** R.G. and Y.Z. conceived the project. Y.Z., D.P.C. and R.G. designed
240 the research and developed the method. Y.Z., J.Y.K. and D.P.C. developed the software and or-
241 ganized the usage manual and tutorial. Y.Z. and S.H.J. designed the auto-gating strategy. Y.T.
242 and M.F. manually gated the protein data to provide a gold standard for the cell type annota-
243 tion. R.G., P.A.S. and K.D.S provided feedback and suggestions as the project progressed. All
244 authors contributed to the preparation of the manuscript.

245 **Competing Interests** R.G. has received consulting income from Takeda and Sanofi and dis-
246 closes ownership in Ozette Technologies. Additionally, R.G. declares research collaborations
247 with Owkin and 10X Genomics. Other authors declare no competing financial interests.



249 **Figure 1 ADTnorm normalization model, function and performance.** **A.** ADT-
 250 norm takes in the ADT expression matrix after routine quality control steps. The nor-
 251 malization procedure starts with the identification of landmarks (peaks and valleys)
 252 in the expression density distribution for each protein marker of each batch. Then,
 253 detected peaks and valleys are aligned across batches through functional data anal-
 254 ysis. The landmark alignment normalization integrates CITE-seq data from different

255 sources. The detected peaks and valleys can also be used for automatic threshold-
256 gating (auto-gating) and antibody staining quality evaluation, which can guide the se-
257 lection of CITE-seq antibodies and staining concentrations. **B.** Comparison of ADT
258 expression distribution across studies of three T cell lineage markers (CD3, CD4 and
259 CD8) after normalization by Arcsinh, CLR or ADTnorm. UMAP embeddings colored
260 by study or cell type were generated after the normalization of 9 ADT markers shared
261 across all 13 studies. ADTnorm was provided “study” as the batch key. Cell type
262 annotations were defined by manual threshold-gating by two immunologists on each
263 sample separately, independent of the normalization work in this paper (Methods).
264 The corresponding manual gating strategy is summarized in Supplementary Table 2.
265 **C.** Study-level batch correction and broad-level cell type separation quantified by Sil-
266 houette score and Adjusted Rand Index (ARI) across various ADT transformation and
267 normalization approaches (Methods). ADTnorm was applied using default parameters
268 or customized landmark alignment adjustments. Gray arrows indicate the direction of
269 improved integration performance, i.e., minimized batch effect and maximized cell type
270 separation. The vertical and horizontal error bars represent the standard deviations of
271 20 bootstrap samples for each normalization method. **D.** Violin plots displaying CD19
272 expression for each cell in the 10X_malt_10k dataset following normalization under the
273 severe imbalanced setting (Methods). Abnormal artifacts introduced to specific cell
274 types during the normalization are highlighted by red squares. **E.** Average auto-gating
275 accuracy across cell types (x-axis) and studies (colors). **F.** Averaged stain quality
276 quantification across protein markers (x-axis) and studies (colors). The central boxes
277 of **D-F** represent the interquartile range (IQR), which contains the middle 50% of the
278 data. The line inside the box indicates the median. The whiskers extend to the small-
279 est and largest values within 1.5 times the IQR from the lower and upper quartiles,
280 respectively. **B, E** and **F** share the same color legend for studies.



282 **Figure 2 ADTnorm application to antibody titration determination and COVID-**
 283 **19 related disease study. A.** ADT expression distributions of three T cell lineage
 284 markers (CD3, CD4 and CD8) across samples stained at 1/25, 1/5, 1 and 2 times the
 285 commercially recommended antibody concentration following normalization by Arc-
 286 sinh, CLR or ADTnorm. UMAP displayed the batch correction across the four antibody
 287 concentrations and cell-type separation using 124 ADT markers provided by the origi-
 288 nal paper¹⁷. **B.** Stain quality score is utilized to determine the positive population and
 289 negative population separation power (Methods). The lowest titration with sufficient
 290 separation of positive and negative cells (dashed line indicates stain quality score of
 291 5) is highlighted for each protein marker with increased saturation. **C.** Data integration
 292 across three research institutes where CITE-seq was generated. UMAP shows the
 293 batch correction across three research institutes and cell type separation compared
 294 across Arcsinh, CLR, DSB and ADTnorm. DSB is the normalization method used
 295 in the original paper¹³. UMAPs were constructed on 192 ADT markers colored by
 296 research institute or cell type. **D.** Volcano plots displaying results of differential propor-
 297 tion of the positive cells for each protein marker between healthy donors and COVID-19

298 patients. The differential detection analysis was done for CD14⁺ Monocytes, CD16⁺
299 Monocytes and CD83⁺ CD14⁺ Monocytes, respectively. Cell type labels are from the
300 original publication¹³ of the COVID-19 data. **E.** Dot plot displays consistently differen-
301 tially expressed protein markers, i.e., CD38, CD64 and CD169, across three monocyte
302 subsets. Points are colored by the average normalized ADT expression and the dot
303 size is relative to the proportion of cells with positive-expression in healthy donors or
304 COVID-19 patients.

305 **Methods**

306 **Data source and pre-processing**

307 Public CITE-seq datasets were downloaded through URLs summarized in Supplementary
308 Table 1. Datasets are identified by the first author’s last name or by “10X” for data obtained
309 from the 10X genomics websites. Empty droplets, cell aggregates, and apoptotic cells were
310 removed from each dataset based on total UMI counts and the percentage of mitochondrial
311 gene expression using the *PerCellQCMetrics* and *isOutlier* functions using default parameter
312 values from the *scuttle* R package⁴¹. ADTnorm was then applied to the raw CITE-seq protein
313 expression data after quality checks and cell filtering.

314 **ADTnorm normalization and integration pipeline**

315 **Landmark Detection.** ADTnorm first Arcsinh-transforms raw ADT counts, then identifies
316 landmarks (peaks and valleys) in the density distribution of protein expression. Peaks are
317 defined as local maxima within high-density regions (Supplementary Fig. 1A), and a curve
318 registration algorithm²⁶ is employed to identify all detectable peak locations. Between each
319 adjacent pair of peaks, ADTnorm identifies valleys as local minima. In scenarios where only
320 one peak is detected or in cases involving a shoulder peak (Supplementary Fig. 1C), valley
321 detection depends on the density slope transitioning from the negative peak to the distribution’s
322 right tail or shoulder peak. Peak and valley detection accuracy relies on precise kernel density
323 estimation for each sample, making selecting a practical bandwidth crucial. The search for an
324 appropriate bandwidth begins with a relatively large value. If no or only one peak is detected
325 with this broader bandwidth, the search continues with narrower settings. For markers gener-
326 ally exhibiting multiple peaks, like CD4, an even narrower bandwidth is applied. Users can
327 input prior information into the ADTnorm software to assist in selecting the optimal bandwidth
328 for constructing the ADT density distribution.

329 CITE-seq ADT counts are discrete, unlike the continuous data from flow cytometry, with
330 negative peaks often close to zero. Although the Arcsinh transformation effectively compresses
331 large ADT counts into a more manageable range similar to log transformation, it remains nearly
332 linear for counts near zero. Therefore, Arcsinh transformation potentially results in artificial
333 peaks at this low range due to the discrete values. To eliminate suspicious negative peaks,
334 ADTnorm merges peaks detected below a certain small threshold (*neg_candidate_thres* defined
335 by users in *ADTnorm* function) near zero or applies a larger bandwidth to smooth these ar-
336 eas. Additionally, if the quality control and filtering steps are insufficiently rigorous, leaving
337 empty droplets, a minor enriched peak might appear near zero before the true negative peak.
338 ADTnorm is designed to recognize and disregard such spurious peaks. Conversely, doublets
339 might create false positive peak landmarks outside the typical range. ADTnorm uses the mean
340 absolute deviation (MAD, *mad* function in the *stats* R package with default values) to assess
341 whether a positive peak landmark is an outlier, excluding it from peak alignment procedures.
342 Similarly, outlier valley landmarks that substantially deviate from the typical range of valley
343 values across samples within the same batch are identified by MAD and adjusted to the average

344 valley locations of neighboring samples, i.e., samples with higher protein expression distribu-
345 tion similarity. Such similarity distance between pair of samples is quantified using the earth
346 mover’s distance (EMD, *calculate_emd_gene* function in the *EMDomics* R package with default
347 values)⁴² based on the ADT count density distribution for each protein marker.

348 **Landmark Alignment.** ADTnorm leverages identified peaks and valleys in ADT density distri-
349 butions to mitigate technical variations across batches, studies, platforms, and other experimen-
350 tal inconsistencies by aligning these landmarks across samples. This landmark alignment strat-
351 egy is inspired by methodologies like *guassNorm* and *fdaNorm*²⁵, initially developed for flow
352 cytometry data. Specifically, ADTnorm utilizes functional data analysis, employing a warping
353 function²⁷ to perform a one-to-one transformation of ADT expression that uniformly adjusts the
354 ADT density distribution in a monotone fashion. Mathematically, the kernel density estimate
355 for each sample i is represented by a B-spline interpoland x_i . The peak(s) and valley(s) de-
356 tected for each sample serve as landmarks, and the landmark locations are denoted by t_{ij} where
357 $j = 1, \dots, m$. m is 2, meaning there is only one peak and one valley, and m is 3, indicating that
358 this sample has two peaks and one valley. To align the peaks and valleys across sample, x_i is
359 transformed by a strictly monotone and invertible function h_i known as a warping function for
360 sample i , such that $h_i(T_{start}) = T_{start}$ where T_{start} is the starting point of the ADT expression
361 value range and $h_i(T_{end}) = T_{end}$ where T_{end} is the ending point of the ADT expression value
362 range. Also, $h_i(t_{0j}) = t_{ij}$ for $j = 1, \dots, m$, representing the transformation of the density curves
363 x_i so that the corresponding landmark j align to a fixed location t_{0j} . By default, t_{0j} is set to
364 the mean value of t_{ij} across samples, but users can pre-defined the target landmark alignment
365 locations (*target_landmark_location* parameter in *ADTnorm* function). To obtain the optimal
366 estimation of h_i , the target function is set to minimizing $\int ||y(t) - xh(t)||^2 dt + \lambda \int \omega^2(t) dt$
367 where y is a fixed function in the same class as x_i and $\omega(t)$ measures the relative curvature of h .
368 This penalty on the relative curvature ensures that the transformation function is both smooth
369 and monotone.

370 Note that ADTnorm also allows users to provide prior information to more properly align
371 positive peaks across samples. For instance, in batches exclusively involving T cells (e.g.,
372 *buus_2021_T*), a single positive peak for CD3 protein markers is expected. By providing a list
373 of such batches and markers, ADTnorm can precisely align the detected peak to the positive
374 peaks in other samples, ensuring consistent and accurate peak alignment (Supplementary Note).
375 This functionality underscores ADTnorm’s adaptability and effectiveness in handling various
376 experimental conditions and study designs. ADTnorm can be applied to integrate batch effects
377 across studies (Supplementary Fig. 2) or batch effects between individual samples within stud-
378 ies, e.g., each donor is a batch (Supplementary Fig. 3 and Supplementary Note). Furthermore,
379 by ignoring missing values, ADTnorm can be used to integrate ADT expression for markers
380 profiled in some but not all batches, a capability not shared by all normalization methods (Sup-
381 plementary Note).

382 **Default and customized ADTnorm normalization settings**

383 In the benchmark analysis with 14 existing methods, ADTnorm normalized the 13 pub-

384 lic datasets using default landmark detection (default) or GUI-assisted manually adjusted
385 landmark detection (customized). The default setting applied the default parameter values
386 of the *ADTnorm* R function, which can handle general protein expression normalization
387 scenarios. *ADTnorm* R function offers adjustable parameters to refine landmark detection
388 and provides intermediate density plot visualizations, allowing users to verify the reason-
389 ableness of detected peaks and valleys and landmarks alignment. A detailed tutorial (Sup-
390 plementary Note and at [https://yezhengstat.github.io/ADTnorm/articles/](https://yezhengstat.github.io/ADTnorm/articles/ADTnorm-tutorial.html)
391 [ADTnorm-tutorial.html](https://yezhengstat.github.io/ADTnorm/articles/ADTnorm-tutorial.html)) is available to facilitate ADTnorm’s usage, offering guidance
392 on software utilization and parameter adjustment to accommodate different protein expression
393 characteristics. Additionally, a GUI implemented using the R shiny function (Supplementary
394 Fig. 1B) is available to help users manually fine-tune landmark locations for tailored protein
395 normalization. The customized setting used in the benchmark analysis relied on manually fine-
396 tuning the peak and valley landmarks to ensure the optimal landmark alignment.

397 **Weighted nearest neighbor integration of the RNA and protein**

398 Multimodal embeddings were evaluated to test the ADT integration performance of ADT-
399 norm and existing methods. The RNA components are integrated using the *Seurat* reciprocal
400 PCA (RPCA) strategy. Specifically, the raw gene expression data are first normalized by log-
401 transformation of count per million (log CPM), and the top 5000 feature genes are selected
402 by the “*vst*” method. Then, the normalized RNA data are scaled using the top features, fol-
403 lowed by principal component analysis (PCA) for each study, respectively. Integration an-
404 chors are obtained by *FindIntegrationAnchors* function of *Seurat* using the RPCA reduction
405 method. We confirmed the RNA component integration performance by visualizing in UMAP
406 and color-coded by batch and cell types in Supplementary Fig. 5A. The weighted nearest neigh-
407 bor (WNN) strategy¹⁰ from *Seurat* is leveraged to further integrate the harmonized RNA and
408 normalized protein components. Specifically, the *FindMultiModalNeighbors* function from
409 *Seurat* is used to construct the WNN graph based on the top 30 PCs of the RNA component
410 and the top 15 PCs of the protein component. We use default values for all other parameters in
411 the above-mentioned across-modality integration pipeline.

412 **Robustness evaluation on normalization methods by the imbalanced cell type constitution**

413 To assess the robustness of normalization methods, we filtered the 13 public datasets to
414 create three subsets of the data with different cell-type compositions. In the default integration
415 setting, which we used to illustrate the ADTnorm model and performance, one dataset out of
416 13 public datasets, i.e., *buus_2021_T*, was filtered to only contain one sample of 666 T cells.
417 The other 12 datasets profile total PBMCs. This default setting creates a mild imbalanced
418 scenario for data integration. To test integration performance with moderately imbalanced
419 subset compositions across batches, we kept only T cells in the *hao_2020* and *triana_2021*
420 studies (24 samples and nine samples, respectively). Furthermore, filtering and only keeping
421 CD8 T cells in the *triana_2021* study and T cells from *hao_2020* and *buus_2021* studies formed
422 the severely imbalanced cell-type composition. We evaluated the normalized expression for
423 the CD19 and CD4 across major cell types on the *10X_pbmc_10k* and *10X_malt_10k* datasets,

424 which contain one sample per study and the full data from the original studies were kept.

425 **Stain quality score**

426 To determine the optimal concentration of antibodies to stain specific protein markers,
427 we proposed a stain quality score designed for ADT data. The stain quality score is inspired
428 by the stain index widely used to optimize the quality and effectiveness of fluorescent staining
429 of cells in flow cytometry⁴³. The stain index is defined as the ratio of the separation between
430 the positive and negative peaks divided by two times the standard deviation of the negative
431 population.

$$\text{Stain Index} = \frac{\text{Positive Peak Mode Location} - \text{Negative Peak Mode Location}}{2 \times SD(\text{Negative Peak})}$$

432 To extend the stain index to capture separation in more diverse data distribution patterns
433 beyond bimodal expression, such as multiple peaks, shoulder peaks or heavy right tail (Supple-
434 mentary Fig. 1C), we designed the stain quality score as follows:

$$\begin{aligned} \text{Stain Quality Score}_{2\text{peaks}} &= \frac{\text{PosPeakMode} - \text{NegPeakMode}}{SD(\text{NegPeak}) + SD(\text{PosPeak})} \\ &\times (\text{PosPeakHeight} - \text{ValleyHeight} + 1) \\ &* (AUC(\text{PosPeak}) + 1) \end{aligned}$$

435 $AUC(\text{PosPeak})$ means the area under the curve of the positive peak in the corresponding
436 density distribution. Therefore, the stain quality for protein markers with two peaks is positively
437 correlated with the peak mode distance, the sharpness of the positive peak and the proportion
438 of the positive population, and negatively correlated with the total standard deviation in the
439 negative and positive populations.

$$\begin{aligned} \text{Stain Quality Score}_{3+\text{peaks}} &= \frac{\text{RightMostPeakMode} - \text{NegPeakMode}}{\sum(SD(\text{EachPeak}))} \\ &\times (\text{RightMostPeakHeight} - \text{RightMostValleyHeight} + 1) \\ &* (AUC(\text{NonNegPeak}) + 1) \end{aligned}$$

440 For protein markers with three or more peaks, the stain quality score is positively correlated
441 with the landmark distance between the right-most peak and the negative peak, the sharpness of
442 the most positive peak and the proportion of non-negative populations. The score is negatively
443 correlated with the sum of the standard deviation of each peak.

$$\text{StainQualityScore}_{1\text{peak}} = \frac{\text{Valley} - \text{PeakMode}}{SD(\text{AllData})} \times (0 - \text{ValleyHeight} + 1) * (AUC(\text{RightTail}) + 1)$$

444 Due to the missing positive peak, for markers with one detected peak, we use the distance
445 between peak and valley as the lower bound of the distance between any positive population
446 and the negative peak mode. We continue to penalize the score for one peak by setting the
447 *PosPeakHeight* to be 0. The area under the curve of the right tail beyond the valley is used
448 to distinguish markers that only have a negative population and markers with a heavy right tail
449 or even a shoulder peak. In other words, although the independent positive peak failed to be
450 detected, the positive population is still present.

451 Stain quality scores are comparable across markers with different peak numbers and gener-
452 ally give higher scores to markers with more peaks. For markers with the same number of
453 identified peaks, better separation of positive and negative populations (longer distance between
454 peak modes) and sharper peaks (lower standard deviation) leads to higher stain quality scores.
455 Markers with two identified peaks score higher than those exhibiting only a shoulder peak.
456 Distributions with only one identified peak and a heavy right tail will have a lower score, and
457 distributions with only one peak and no right tail will be given the lowest score. Supplementary
458 Fig. 1C provided the diagram illustrating the peak patterns and associated stain quality score
459 order.

460 **Computational environment for evaluating runtime and memory**

461 Software performance assessments (Supplementary Fig. 4D-E) were conducted on a ded-
462 icated server at Fred Hutchinson Cancer Center in terms of running time and memory consump-
463 tion. The server was equipped with an Intel(R) Xeon(R) Gold 6254 CPU @3.10GHz, featuring
464 18 cores, 36 threads, and 754GB RAM. For GPU-accelerated tasks, an NVIDIA-SMI GPU
465 with 12GB of VRAM was utilized. The computational environment was hosted on Ubuntu
466 18.04.6 LTS, with kernel version 4.15.0-213-generic. The software was compiled and run us-
467 ing GCC version 8.3.0 and CUDA toolkit 12.2. Evaluations were performed under minimal
468 system load to ensure consistent and reproducible results.

469 **Data availability**

470 The raw data used in the paper were downloaded from multiple sources depending on the
471 original studies. Supplementary Table 1 summarized the data source and accession. The cor-
472 responding processed data for the 13 public studies were uploaded as demo data to be part of
473 the ADTnorm software repository ([https://github.com/yezhengSTAT/ADTnorm/
474 tree/main/data](https://github.com/yezhengSTAT/ADTnorm/tree/main/data)).

475 **Code availability**

476 ADTnorm package is implemented in R and is accompanied by a Python wrapper of the
477 R function. The source codes and detailed instructions for running ADTnorm are publicly
478 available at <https://github.com/yezhengSTAT/ADTnorm> for the R package and
479 <https://github.com/donnafarberlab/ADTnormPy> for the Python wrapper.

- 481 1. Stoeckius, M., Hafemeister, C., Stephenson, W., Houck-Loomis, B., Chattopadhyay, P.K.,
482 Swerdlow, H., Satija, R., Smibert, P.: Simultaneous epitope and transcriptome measure-
480 ment in single cells. *Nature methods* **14**(9) (2017) 865–868
483
- 484 2. Shahi, P., Kim, S.C., Haliburton, J.R., Gartner, Z.J., Abate, A.R.: Abseq: Ultrahigh-
485 throughput single cell protein profiling with droplet microfluidic barcoding. *Scientific*
486 *reports* **7**(1) (2017) 1–12
- 487 3. Peterson, V.M., Zhang, K.X., Kumar, N., Wong, J., Li, L., Wilson, D.C., Moore, R., Mc-
488 Clanahan, T.K., Sadekova, S., Klappenbach, J.A.: Multiplexed quantification of proteins
489 and transcripts in single cells. *Nature biotechnology* **35**(10) (2017) 936–939
- 490 4. Mimitou, E.P., Cheng, A., Montalbano, A., Hao, S., Stoeckius, M., Legut, M., Roush, T.,
491 Herrera, A., Papalex, E., Ouyang, Z., et al.: Multiplexed detection of proteins, transcrip-
492 tomes, clonotypes and crispr perturbations in single cells. *Nature methods* **16**(5) (2019)
493 409–412
- 494 5. Caron, D.P., Specht, W.L., Chen, D., Wells, S.B., Szabo, P.A., Jensen, I.J., Farber, D.L.,
495 Sims, P.A.: Multimodal hierarchical classification of cite-seq data delineates immune cell
496 states across lineages and tissues. *bioRxiv* (2023)
- 497 6. Wells, S.B., Rainbow, D.B., Mark, M., Szabo, P.A., Ergen, C., Maceiras, A.R., Caron, D.P.,
498 Rahmani, E., Benuck, E., Amiri, V.V.P., et al.: Multimodal profiling reveals tissue-directed
499 signatures of human immune cells altered with age. *bioRxiv* (2024) 2024–01
- 500 7. Zhou, Z., Ye, C., Wang, J., Zhang, N.R.: Surface protein imputation from single cell
501 transcriptomes by deep neural networks. *Nature communications* **11**(1) (2020) 651
- 502 8. Lakkis, J., Schroeder, A., Su, K., Lee, M.Y., Bashore, A.C., Reilly, M.P., Li, M.: A
503 multi-use deep learning method for cite-seq and single-cell rna-seq data integration with
504 cell surface protein prediction and imputation. *Nature machine intelligence* **4**(11) (2022)
505 940–952
- 506 9. Zhou, S., Li, Y., Wu, W., Li, L.: scmnt: a multi-use deep learning approach for cell anno-
507 tation, protein prediction and embedding in single-cell rna-seq data. *Briefings in Bioinfor-*
508 *matics* **25**(2) (2024) bbad523
- 509 10. Hao, Y., Hao, S., Andersen-Nissen, E., Mauck III, W.M., Zheng, S., Butler, A., Lee, M.J.,
510 Wilk, A.J., Darby, C., Zager, M., et al.: Integrated analysis of multimodal single-cell data.
511 *Cell* **184**(13) (2021) 3573–3587
- 512 11. Guilliams, M., Bonnardel, J., Haest, B., Vanderborcht, B., Wagner, C., Remmerie, A.,
513 Bujko, A., Martens, L., Thoné, T., Browaeys, R., et al.: Spatial proteogenomics reveals
514 distinct and evolutionarily conserved hepatic macrophage niches. *Cell* **185**(2) (2022) 379–
515 396

- 516 12. Zhang, X., Song, B., Carlino, M.J., Li, G., Ferchen, K., Chen, M., Thompson, E.N., Kain,
517 B.N., Schnell, D., Thakkar, K., et al.: An immunophenotype-coupled transcriptomic atlas
518 of human hematopoietic progenitors. *Nature Immunology* (2024) 1–13
- 519 13. Stephenson, E., Reynolds, G., Botting, R.A., Calero-Nieto, F.J., Morgan, M.D., Tuong,
520 Z.K., Bach, K., Sungnak, W., Worlock, K.B., Yoshida, M., et al.: Single-cell multi-omics
521 analysis of the immune response in covid-19. *Nature medicine* **27**(5) (2021) 904–916
- 522 14. Baysoy, A., Bai, Z., Satija, R., Fan, R.: The technological landscape and applications of
523 single-cell multi-omics. *Nature Reviews Molecular Cell Biology* **24**(10) (2023) 695–713
- 524 15. Anderson, N.D., Birch, J., Accogli, T., Criado, I., Khabirova, E., Parks, C., Wood, Y.,
525 Young, M.D., Porter, T., Richardson, R., et al.: Transcriptional signatures associated with
526 persisting cd19 car-t cells in children with leukemia. *Nature Medicine* **29**(7) (2023) 1700–
527 1709
- 528 16. Mulè, M.P., Martins, A.J., Tsang, J.S.: Normalizing and denoising protein expression data
529 from droplet-based single cell profiling. *Nature Communications* **13**(1) (2022) 1–12
- 530 17. Nettersheim, F.S., Armstrong, S.S., Durant, C., Blanco-Dominguez, R., Roy, P., Orec-
531 chioni, M., Suryawanshi, V., Ley, K.: Titration of 124 antibodies using cite-seq on human
532 pbmcs. *Scientific reports* **12**(1) (2022) 20817
- 533 18. Buus, T.B., Herrera, A., Ivanova, E., Mimitou, E., Cheng, A., Herati, R.S., Papagian-
534 nakopoulos, T., Smibert, P., Odum, N., Koralov, S.B.: Improving oligo-conjugated anti-
535 body signal in multimodal single-cell analysis. *Elife* **10** (2021) e61973
- 536 19. Colpitts, S.J., Budd, M.A., Monajemi, M., Reid, K.T., Murphy, J.M., Ivison, S., Verchere,
537 C.B., Levings, M.K., Crome, S.Q.: Strategies for optimizing cite-seq for human islets and
538 other tissues. *Frontiers in Immunology* **14** (2023) 1107582
- 539 20. Lopez, R., Regier, J., Cole, M.B., Jordan, M.I., Yosef, N.: Deep generative modeling for
540 single-cell transcriptomics. *Nature methods* **15**(12) (2018) 1053–1058
- 541 21. Yang, S., Corbett, S.E., Koga, Y., Wang, Z., Johnson, W.E., Yajima, M., Campbell, J.D.:
542 Decontamination of ambient rna in single-cell rna-seq with decontx. *Genome biology* **21**
543 (2020) 1–15
- 544 22. Gayoso, A., Steier, Z., Lopez, R., Regier, J., Nazor, K.L., Streets, A., Yosef, N.: Joint
545 probabilistic modeling of single-cell multi-omic data with totalvi. *Nature methods* **18**(3)
546 (2021) 272–282
- 547 23. Yin, Y., Yajima, M., Campbell, J.D.: Characterization and decontamination of background
548 noise in droplet-based single-cell protein expression data with decontpro. *Nucleic Acids*
549 *Research* **52**(1) (2024) e4–e4

- 550 24. Staats, J., Divekar, A., McCoy, J.P., Maecker, H.T.: Guidelines for gating flow cytometry
551 data for immunological assays. *Immunophenotyping: Methods and Protocols* (2019) 81–
552 104
- 553 25. Hahne, F., Khodabakhshi, A.H., Bashashati, A., Wong, C.J., Gascoyne, R.D., Weng, A.P.,
554 Seyfert-Margolis, V., Bourcier, K., Asare, A., Lumley, T., et al.: Per-channel basis nor-
555 malization methods for flow cytometry data. *Cytometry Part A: The Journal of the Inter-
556 national Society for Advancement of Cytometry* **77**(2) (2010) 121–131
- 557 26. Ramsay, J.O., Li, X.: Curve registration. *Journal of the Royal Statistical Society: Series B*
558 *(Statistical Methodology)* **60**(2) (1998) 351–363
- 559 27. Ramsay, J.O., Wickham, H., Graves, S., Hooker, G.: *fda: Functional data analysis. R*
560 *package version 2*(4) (2014) 142
- 561 28. Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y.,
562 Brenner, M., Loh, P.r., Raychaudhuri, S.: Fast, sensitive and accurate integration of single-
563 cell data with harmony. *Nature methods* **16**(12) (2019) 1289–1296
- 564 29. Haghverdi, L., Lun, A.T., Morgan, M.D., Marioni, J.C.: Batch effects in single-cell rna-
565 sequencing data are corrected by matching mutual nearest neighbors. *Nature biotechnol-
566 ogy* **36**(5) (2018) 421–427
- 567 30. Trussart, M., Teh, C.E., Tan, T., Leong, L., Gray, D.H., Speed, T.P.: Removing unwanted
568 variation with cytotfruv to integrate multiple cytof datasets. *Elife* **9** (2020) e59630
- 569 31. Siddiqui, S., Livák, F.: Principles of advanced flow cytometry: A practical guide. In:
570 *T-Cell Development: Methods and Protocols*. Springer (2022) 89–114
- 571 32. Qin, S., Jiang, Y., Wei, X., Liu, X., Guan, J., Chen, Y., Lu, H., Qian, J., Wang, Z., Lin, X.:
572 Dynamic changes in monocytes subsets in covid-19 patients. *Human Immunology* **82**(3)
573 (2021) 170–176
- 574 33. Horenstein, A.L., Faini, A.C., Malavasi, F.: Cd38 in the age of covid-19: a medical
575 perspective. *Physiological Reviews* **101**(4) (2021) 1457–1486
- 576 34. Karawajczyk, M., Douhan Håkansson, L., Lipcsey, M., Hultström, M., Pauksens, K.,
577 Frithiof, R., Larsson, A.: High expression of neutrophil and monocyte cd64 with si-
578 multaneous lack of upregulation of adhesion receptors cd11b, cd162, cd15, cd65 on
579 neutrophils in severe covid-19. *Therapeutic advances in infectious disease* **8** (2021)
580 20499361211034065
- 581 35. Li, Y., Lee, P.Y., Kellner, E.S., Paulus, M., Switanek, J., Xu, Y., Zhuang, H., Sobel, E.S.,
582 Segal, M.S., Satoh, M., et al.: Monocyte surface expression of fc γ receptor ri (cd64),
583 a biomarker reflecting type-i interferon levels in systemic lupus erythematosus. *Arthritis
584 research & therapy* **12** (2010) 1–12

- 585 36. Doehn, J.M., Tabeling, C., Biesen, R., Saccomanno, J., Madlung, E., Pappé, E., Gabriel,
586 F., Kurth, F., Meisel, C., Corman, V.M., et al.: Cd169/siglec1 is expressed on circulating
587 monocytes in covid-19 and expression levels are associated with disease severity. *Infection*
588 **49** (2021) 757–762
- 589 37. Ortillon, M., Coudereau, R., Cour, M., Rimmelé, T., Godignon, M., Gossez, M., Yonis, H.,
590 Argaud, L., Lukaszewicz, A.C., Venet, F., et al.: Monocyte cd169 expression in covid-19
591 patients upon intensive care unit admission. *Cytometry Part A* **99**(5) (2021) 466–471
- 592 38. Zhang, B., Srivastava, A., Mimitou, E., Stuart, T., Raimondi, I., Hao, Y., Smibert, P., Satija,
593 R.: Characterizing cellular heterogeneity in chromatin state with sccut&tag-pro. *Nature*
594 *biotechnology* **40**(8) (2022) 1220–1230
- 595 39. Mimitou, E.P., Lareau, C.A., Chen, K.Y., Zorzetto-Fernandes, A.L., Hao, Y., Takeshima,
596 Y., Luo, W., Huang, T.S., Yeung, B.Z., Papalexi, E., et al.: Scalable, multimodal profil-
597 ing of chromatin accessibility, gene expression and protein levels in single cells. *Nature*
598 *biotechnology* **39**(10) (2021) 1246–1258
- 599 40. Fiskin, E., Lareau, C.A., Ludwig, L.S., Eraslan, G., Liu, F., Ring, A.M., Xavier, R.J.,
600 Regev, A.: Single-cell profiling of proteins and chromatin accessibility using phage-atac.
601 *Nature biotechnology* **40**(3) (2022) 374–381
- 602 41. McCarthy, D.J., Campbell, K.R., Lun, A.T., Wills, Q.F.: Scater: pre-processing, quality
603 control, normalization and visualization of single-cell rna-seq data in r. *Bioinformatics*
604 **33**(8) (2017) 1179–1186
- 605 42. Hitchcock, F.L.: The distribution of a product from several sources to numerous localities.
606 *Journal of mathematics and physics* **20**(1-4) (1941) 224–230
- 607 43. Shapiro, H.M.: *Practical flow cytometry*. John Wiley & Sons (2005)

Supplementary Table 1: Public CITE-seq data summary

Dataset	Tissue	URL
10X_pbmc_10k	PBMC	https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.0/pbmc_10k_protein_v3
10X_pbmc_1k	PBMC	https://www.10xgenomics.com/resources/datasets/1-k-pbm-cs-from-a-healthy-donor-gene-expression-and-cell-surface-protein-3-standard-3-0-0
10X_pbmc_5k_v3	PBMC	https://www.10xgenomics.com/datasets/5k-human-pbmcs-3-v3-1-chromium-controller-3-1-standard
10X_pbmc_5k_nextgem	PBMC	https://www.10xgenomics.com/resources/datasets/5-k-peripheral-blood-mononuclear-cells-pbm-cs-from-a-healthy-donor-with-cell-surface-proteins-next-gem-3-1-standard-3-1-0
10X_malt_10k	MALT	https://www.10xgenomics.com/resources/datasets/10-k-cells-from-a-malt-tumor-gene-expression-and-cell-surface-protein-3-standard-3-0-0
stuart_2019	Bone Marrow	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128639
granja_2019_bmmc	Bone Marrow	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139369
granja_2019_pbmc	PBMC	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139369
hao_2020	PBMC	https://atlas.fredhutch.org/nygc/multimodal-pbmc/
kotliarov_2020	PBMC	https://nih.figshare.com/articles/dataset/CITE-seq_protein-mRNA_single_cell_data_from_high_and_low_vaccine_responders_to_reproduce_Figs_4-6_and_associated_Extended_Data_Figs_/11349761
witkowski_2020	Bone Marrow	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153358
triana_2021	Bone Marrow	https://figshare.com/projects/Single-cell_proteo-genomic_reference_maps_of_the_human_hematopoietic_system/94469
buus_2021_T	Only keep T cells	https://figshare.com/collections/Improving_oligo-conjugated_antibody_signal_in_multimodal_single-cell_analysis/5018987
Nettersheim_2022	PBMC (Titration)	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE213282
Stephenson_2021	PBMC (COVID-19)	https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-10026

*PBMC: Peripheral Blood Mononuclear Cells; MALT: Mucosa-Associated Lymphoid Tissue.

Supplementary Table 2: Manual gating strategy.

Cell Type	Gating Strategy
B	CD3 ⁻ CD19 ⁺
CD4 T	CD3 ⁺ CD19 ⁻ CD4 ⁺ CD8 ⁻
CD8 T	CD3 ⁺ CD19 ⁻ CD4 ⁻ CD8 ⁺
DC	CD3 ⁻ CD19 ⁻ CD20 ⁻ CD14 ⁻ HLA-DR ⁺ CD56 ⁻ CD16 ⁻
NK	CD3 ⁻ CD19 ⁻ CD20 ⁻ CD14 ⁻ HLA-DR ⁻ CD56 ⁺
Monocytes	CD3 ⁻ CD19 ⁻ CD20 ⁻ CD14 ⁺
naïve B	CD3 ⁻ CD19 ⁺ CD27 ⁻
memory B	CD3 ⁻ CD19 ⁺ CD27 ⁺
naive CD4	CD3 ⁺ CD19 ⁻ CD4 ⁺ CD8 ⁻ CD25 ⁻ CD45RA ⁺ CD45RO ⁻
memory CD4	CD3 ⁺ CD19 ⁻ CD4 ⁺ CD8 ⁻ CD25 ⁻ CD45RA ⁻ CD45RO ⁺
Treg	CD3 ⁺ CD19 ⁻ CD4 ⁺ CD8 ⁻ CD25 ⁺ CD127 ⁻
naive CD8	CD3 ⁺ CD19 ⁻ CD4 ⁻ CD8 ⁺ CD45RA ⁺ CD45RO ⁻
memory CD8	CD3 ⁺ CD19 ⁻ CD4 ⁻ CD8 ⁺ CD45RA ⁻ CD45RO ⁺
plasmacytoid DC	CD3 ⁻ CD19 ⁻ CD20 ⁻ CD14 ⁻ HLA-DR ⁺ CD56 ⁻ CD16 ⁻ CD123 ⁺ CD11c ⁻
myeloid DC	CD3 ⁻ CD19 ⁻ CD20 ⁻ CD14 ⁻ HLA-DR ⁺ CD56 ⁻ CD16 ⁻ CD123 ⁻ CD11c ⁺
CD16 ⁺ NK	CD3 ⁻ CD19 ⁻ CD20 ⁻ CD14 ⁻ HLA-DR ⁻ CD56 ⁺ CD16 ⁺
CD16 ⁻ NK	CD3 ⁻ CD19 ⁻ CD20 ⁻ CD14 ⁻ HLA-DR ⁻ CD56 ⁺ CD16 ⁻
classical monocyte	CD3 ⁻ CD19 ⁻ CD20 ⁻ CD14 ⁺ CD16 ⁻
intermediate monocyte	CD3 ⁻ CD19 ⁻ CD20 ⁻ CD14 ⁺ CD16 ⁺
non-classical CD16 ⁺ monocyte	CD3 ⁻ CD19 ⁻ CD20 ⁻ CD14 ⁻ HLA-DR ⁺ CD56 ⁻ CD16 ⁺

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [ADTnormNMsupplementaryFigures.pdf](#)
- [ADTnormSuppNote.pdf](#)